Search
Spesolimab
go.drugbank.com/drugs/DB15626ApprovedInvestigationalIt is a humanized monoclonal immunoglobulin G1 antibody that was produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology. … [A252220, A252225] Spesolimab received recommendations from the EMA's Committee for Medicinal Products for Human Use (CHMP) to be granted marketing authorization in October 2022 and was finally approved
Products: Spevigo 450 mg/7,5 mL İnfüzyonluk Çözelti Hazırlamak İçin Konsantre, 2 ADETPimozide
go.drugbank.com/drugs/DB01100ApprovedA diphenylbutylpiperidine that is effective as an antipsychotic agent and as an alternative to haloperidol for the suppression of vocal and motor tics in patients with Tourette syndrome.
Categories: Heterocyclic Compounds, 2-Ring, Dopamine D2 Receptor AntagonistsProducts: NOROFREN 2 MG TABLET, 20 ADET, NOROFREN 2 MG TABLET, 10 ADETNadroparin
go.drugbank.com/drugs/DB08813ApprovedInvestigationalWithdrawnIt is derived from porcine sources and has a mean molecular size of 5000 daltons. … Nadroparin is a low molecular weight heparin (LMWH) which, when bound to antithrombin III (ATIII), accelerates the inactivation of factor II and factor Xa.
Mixtures: FRAXIPARINE 0.3 MLProducts: FRAXIPARINE 2850 IU/0.3 ML 2 ENJEKTOR, FRAXIPARINE 3800 IU/0.4 ML 2 ENJEKTORBuserelin
go.drugbank.com/drugs/DB06719ApprovedInvestigationalBuserelin is a synthetic peptide analog of the luteinizing hormone-releasing hormone (LHRH) agonist, which stimulates the pituitary gland's gonadotrophin-releasing hormone receptor (GnRHR).
Products: Suprefact Depot 2 Months, SUPREFACT INJECTABLE 1 mg/mlSirolimus
go.drugbank.com/drugs/DB00877ApprovedInvestigationalSirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island … [L39267] Sirolimus was also investigated in other cancers such as skin cancer, Kaposi’s Sarcoma, cutaneous T-cell lymphomas, and tuberous sclerosis.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexProducts: RAPAMUNE TABLET 2 mg, LIKMUN-EPitavastatin
go.drugbank.com/drugs/DB08860ApprovedInvestigational[A181087, A181406] Evidence has shown that even for low-risk individuals (with <10% risk of a major vascular event occurring within 5 years) statins cause a 20%-22% relative reduction in major cardiovascular … events (heart attack, stroke, coronary revascularization, and coronary death) for every 1 mmol/L reduction in LDL without any significant side effects or risks.
Categories: Heterocyclic Compounds, 2-Ring, Cytochrome P-450 SubstratesProducts: Trolise 2 mg Filmtabletten, LIVALO (TABLET 2 MG)Trastuzumab
go.drugbank.com/drugs/DB00072ApprovedInvestigational[L14015] It is used as a treatment of human epidermal growth factor receptor (HER)-2+ metastatic breast cancer, where there is a proven amplification of the HER-2 oncogene or over-expression of the HER … -2 protein in tumours.
Mixtures: PHESGO® 1200 MG/600 MG, PHESGO® 1200 MG/600 MGCategories: HER2 (Human Epidermal Growth Factor Receptor 2) inhibitorsTirzepatide
go.drugbank.com/drugs/DB15171ApprovedInvestigational[A246265] Tirzepatide was approved by the FDA on May 13, 2022, under the brand name MOUNJARO by the FDA for the treatment of adults with type 2 diabetes, making it the first and only GIP and GLP-1 receptor … Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist.
Categories: Receptors, G-Protein-Coupled, GLP-1 AgonistsProducts: Mounjaro 5 mg/0,5 ml Enjeksiyonluk Çözelti, 1 ADET, Mounjaro 5 mg/0,5 ml Enjeksiyonluk Çözelti, 4 ADETHydroxyzine
go.drugbank.com/drugs/DB00557ApprovedInvestigationalHydroxyzine is a first-generation histamine H<sub>1</sub>-receptor antagonist of the dephenylmethane and piperazine classes that exhibits sedative, anxiolytic, and antiemetic properties. … [A1257,A187589] It was first developed in 1955,[A189726] and has since remained a relatively common treatment for allergic conditions such as pruritus, urticaria, dermatoses, and histamine-mediated pruritus
Mixtures: DOLMARAL®Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesRozanolixizumab
go.drugbank.com/drugs/DB14919ApprovedInvestigational[L47122] This is due to the efficacy demonstrated in the pivotal Phase 3 MycarinG study (NCT03971422).[L47122] Rozanolixizumab was also approved by the European Commission on January 5, 2024.[L50973] … Rozanolixizumab is a humanized high-affinity anti-human neonatal Fc receptor (FcRn) monoclonal antibody (IgG4P) targeting the immunoglobulin G (IgG).
Products: Rystiggo 280 mg/2 ml Enjeksiyonluk Çözelti, 1 adet